MBIO Share Price | Mustang Bio, Inc. Stock Analysis & Recommendation

Q: What does Mustang Bio, Inc. do?

Overview: Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on cell and gene therapy for hematologic cancers, solid tumors, and rare genetic diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.Financial Snapshot: Most recent Net Sales: Not available. Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025). Market-cap: USD 4.47 Million (Micro Cap).Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -3.94. Return on Equity: -194.57%. Price to Book: 1.24.Contact Details: Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667. Tel: 1 781 6524507. Website: http://www.mustangbio.com/.

Q: Is Mustang Bio, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Mustang Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. Bollinger Bands indicate a bullish weekly trend but a mildly bearish monthly trend. Moving averages are bearish on the daily, and KST is bullish weekly but bearish monthly. Dow Theory reflects a mildly bullish stance on both time frames, and OBV is mildly bullish weekly and bullish monthly.In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -81.69% compared to the S&P 500's 12.22%, and a one-year return of -87.24% against the S&P's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

36.92 k

Shareholding (Sep 2025)

FII

0.04%

Held by 5 FIIs

DII

99.09%

Held by 1 DIIs

Promoter

0.00%

How big is Mustang Bio, Inc.?

22-Jun-2025

As of Jun 18, Mustang Bio, Inc. has a market capitalization of 4.47 million, with net sales of 0.00 million and a net profit of -10.71 million over the latest four quarters. The balance sheet shows shareholder's funds of -3.87 million and total assets of 9.31 million.

View full answer

What does Mustang Bio, Inc. do?

22-Jun-2025

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on cell and gene therapy for hematologic cancers, solid tumors, and rare genetic diseases. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $4.47 million and has no recent net sales or profits.

View full answer

Who are in the management team of Mustang Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Mustang Bio, Inc. includes Executive Chairman Michael Weiss, President and CEO Dr. Manuel Litchman, and Directors Dr. Lindsay Rosenwald, Adam Chill, Neil Herskowitz, and Dr. Michael Zelefsky. They oversee the company's strategic direction and operations.

View full answer

Is Mustang Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Mustang Bio, Inc. has a mildly bearish trend, with mixed technical indicators showing underperformance against the S&P 500, including a year-to-date return of -81.69% compared to the S&P's 12.22%.

View full answer

Compare Mustang Bio, Inc. with Similar Stocks

Lipocine, Inc.Aprea Therapeutics, Inc.NanoViricides, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.94

Return on Equity

-13.22%

Price to Book

0.66

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-37.52%

6 Months

-46.45%

1 Year

-73.04%

2 Years

-98.83%

3 Years

9.33%

4 Years

-99.9%

5 Years

-99.98%

Mustang Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

14.24%

EBIT to Interest (avg)

-30.76

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-3.94

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.36%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.50

EV to EBIT

1.13

EV to EBITDA

1.21

EV to Capital Employed

0.83

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

73.41%

ROE (Latest)

-194.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (0.87%)

Foreign Institutions

Held by 5 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 90.24% vs 49.38% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "-5.60",
          "chgp": "83.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-8.20",
          "chgp": "90.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 69.38% vs 33.42% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.70",
          "val2": "-48.50",
          "chgp": "75.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.70",
          "val2": "-2.80",
          "chgp": "-32.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.80",
          "val2": "-51.60",
          "chgp": "69.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.90

-5.60

83.93%

Interest

0.00

Exceptional Items

0.00

-2.60

100.00%

Consolidate Net Profit

-0.80

-8.20

90.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 90.24% vs 49.38% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.70

-48.50

75.88%

Interest

0.00

1.30

-100.00%

Exceptional Items

-3.70

-2.80

-32.14%

Consolidate Net Profit

-15.80

-51.60

69.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 69.38% vs 33.42% in Dec 2023

All Annual Results

Company CV

About Mustang Bio, Inc.

Mustang Bio, Inc.

Pharmaceuticals & Biotechnology

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).

Company Coordinates

Company Details

2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667

Tel: 1 781 6524507

http://www.mustangbio.com/

Registrar Details

Mustang Bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Mustang Bio, Inc.?

Watch in Real-Time

What does Mustang Bio, Inc. do?

Who are in the management team of Mustang Bio, Inc.?

Is Mustang Bio, Inc. technically bullish or bearish?

Compare Mustang Bio, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Mustang Bio, Inc.

Company Coordinates